Loading clinical trials...

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer (NK) Cells for Advanced Pancreatic Cancer

NCT02718859•Fuda Cancer Hospital, Guangzhou

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporation（IRE）and nature killer(NK) cells for advanced pancreatic cancer.

Detailed Description

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using irreversible electroporation（IRE）and nature killer（NK） cells for advanced pancreatic cancer. The efficacy will be evaluated according to relief degree,progress free survival(PFS) and overall survival(OS). The safety will be evaluated by statistics of adverse reaction

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age:18-80
•2. Diagnosis：advanced and active pancreatic cancer
•3. The tumour is measurable
•4. Eastern Cooperative Oncology Group(ECOG) score：0\~2；3 but has no relationship with tumour
•5. Vital organ function is normal:
•total bilirubin(TB) \<68μmol/L aspartate aminotransferase(AST)\<90 IU/L Cre\<353μmol/L white blood cell count(WBC)\<9×10\^9/L,when WBC is close to or even greater than 9×10\^9/L，the recommended dose should be halved platelet count(PLT)\>80×10\^9/L Red blood cell specific volume(HCT)\>0.20 Non severe viral or bacterial infection
•6. Non pregnant and lactating patients
•7. Non allergic reactions to biological products
•8. Informed and consent

Exclusion Criteria

•1. Patients with cardiac pacemaker
•2. Patients with severe cardiac and pulmonary dysfunction
•3. Patients that the researchers do not think fit into the group,including patients failed in compliance assessment

Locations (1)

Central laboratory in Fuda cancer hospital

Guangzhou, Guangdong, China

Key Dates

Start Date

March 1, 2016

Primary Completion Date

March 1, 2017

Completion Date

March 1, 2019

Last Updated

September 12, 2019

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

NK cells

BIOLOGICAL

irreversible electroporation (IRE )

PROCEDURE

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients